Chardan raised the firm’s price target on Oculis (OCS) to $51 from $33 and keeps a Buy rating on the shares. Oculis announced that privosegtor will advance into two registrational studies for acute optic neuritis and one for non-arteritic anterior ischemic optic neuritis, accelerating timelines relative to prior guidance, the analyst tells investors in a research note. The update reflects the company’s growing confidence in the asset following strong Phase 2 ACUITY AON results earlier this year.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $30 from $28 at BofA
- Oculis price target raised to $36 from $33 at H.C. Wainwright
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
- Oculis initiated with a Buy at Needham